hemonc.tv
Evolving Treatments in Acute Myeloid Leukemia
http://www.hemonc.tv/Home/Leukemia/AllLeukemiaArticles/EvolvingTreatmentsinAcuteMyeloidLeukemia.aspx
You are here :. Evolving Treatments in Acute Myeloid Leukemia. Renal Cell Carcinoma (Kidney). Evolving Treatments in Acute Myeloid Leukemia. Gail J. Roboz, MD, Associate Professor of Medicine, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York. Could you give some background on acute myeloid leukemia (AML)? How does AML prognosis compare with other hematologic malignancies? A recent survey by Sant and colleagues was published in the. Describing hematologic mal...
hemonc.tv
Should Lung Cancer Screening With Low-Dose Computed Tomography Be Routine for Smokers and Former Smokers?
http://www.hemonc.tv/Home/LungCancer/AllLungCancerArticles/ShouldLungCancerScreeningWithLow-DoseComputedTomographyBeRoutineforSmokersandFormerSmokers.aspx
You are here :. All Lung Cancer Articles. Should Lung Cancer Screening With Low-Dose Computed Tomography Be Routine for Smokers and Former Smokers? Renal Cell Carcinoma (Kidney). Should Lung Cancer Screening With Low-Dose Computed Tomography Be Routine for Smokers and Former Smokers? Clinical Advances in Hematology and Oncology. October 2014, Volume 12, Issue 10. Should Low-Dose CT Be Routine in These Patients? James R. Jett, MD, is a professor of medicine at National Jewish Health in Denver, Colorado.
hemonc.tv
Bevacizumab vs EGFR Antibodies in Metastatic Colorectal Cancer
http://www.hemonc.tv/Home/ColorectalCancer/AllColorectal(GI)Articles/BevacizumabvsEGFRAntibodiesinMetastaticColorectalCancer.aspx
You are here :. Bevacizumab vs EGFR Antibodies in Metastatic Colorectal Cancer. Renal Cell Carcinoma (Kidney). Bevacizumab vs EGFR Antibodies in Metastatic Colorectal Cancer. Alan P. Venook, MD, Professor, Department of Medicine, Hematology/Oncology, University of California, San Francisco. What are the benefits and limitations of bevacizumab in metastatic colorectal cancer? What are the benefits and limitations of epidermal growth factor receptor (EGFR) antibodies for metastatic colorectal cancer? Wild-...
hemonc.tv
Education
http://www.hemonc.tv/Education.aspx
You are here :. Renal Cell Carcinoma (Kidney). The CME/CE courses at HemOnc.tv cover a wide range of topics important to the practicing health care provider. We invite you to browse through the menu below where you'll find programs on a wide range of disease states and related issues. Neuroendocrine Tumors - NETs. Renal Cell Carcinoma (Kidney). Currently viewing : Lecture Series. 2014 Society of Hematologic Oncology Annual Meeting - Session X - Conference Highlights. And MD Anderson Cancer Center. Treatm...
hemonc.tv
Ibrutinib combined with bendamustine and rituximab in previously treated CLL/SLL: First results phase III study - Leukemia - Videos :: HemOnc
http://www.hemonc.tv/Videos/TabId/1811/VideoId/1397/Ibrutinib-Combined-With-Bendamustine-And-Rituximab-In-Previously-Treated-CLLSLL-First-Results-Phase-III-Study.aspx
You are here :. Renal Cell Carcinoma (Kidney). The HemOncTV Network is a way to learn and interact with your peers. If you’d like to find out more about this topic you may submit a question regarding the current video playing in "Ask the Experts". Please select a video from the list below. Ibrutinib combined with bendamustine and rituximab in previously treated CLL/SLL: First results phase III study. ASCO 2015 - Abstract LBA7005 Link to website. Please enter the Question! Please enter your Email Address!
hemonc.tv
ASPECCT phase 3 study of pmab vs cmab in chemorefractory wild-type KRAS exon 2 mCRC - GI/Colorectal Cancer - Videos :: HemOnc
http://www.hemonc.tv/Videos/TabId/1811/VideoId/1398/ASPECCT-Phase-3-Study-Of-Pmab-Vs-Cmab-In-Chemorefractory-Wildtype-KRAS-Exon-2-MCRC.aspx
You are here :. Renal Cell Carcinoma (Kidney). The HemOncTV Network is a way to learn and interact with your peers. If you’d like to find out more about this topic you may submit a question regarding the current video playing in "Ask the Experts". Please select a video from the list below. ASPECCT phase 3 study of pmab vs cmab in chemorefractory wild-type KRAS exon 2 mCRC. ASCO 2015 - Abstract 3586 (jpg). Use the space below to submit your questions to the HemOnc.TV Experts. (Login required.). Review of ...
hemonc.tv
Targeted Therapy vs Chemotherapy: Which Has Had More Impact on Survival in Lung Cancer?
http://www.hemonc.tv/Home/LungCancer/AllLungCancerArticles/TargetedTherapyvsChemotherapyWhichHasHadMoreImpactonSurvivalinLungCancer.aspx
You are here :. All Lung Cancer Articles. Targeted Therapy vs Chemotherapy: Which Has Had More Impact on Survival in Lung Cancer? Renal Cell Carcinoma (Kidney). Targeted Therapy vs Chemotherapy: Which Has Had More Impact on Survival in Lung Cancer? Clinical Advances in Hematology and Oncology. November 2014, Volume 12, Issue 11. Chemotherapy and targeted therapy both have earned their place in the treatment of lung cancer, but which has made the larger contribution? HARD TO PROVE, BUT IMPOSSIBLE TO IGNORE.
hemonc.tv
Videos
http://hemonc.tv/Videos.aspx
You are here :. Renal Cell Carcinoma (Kidney). The HemOncTV Network is a way to learn and interact with your peers. If you’d like to find out more about this topic you may submit a question regarding the current video playing in "Ask the Experts". Please select a video from the list below. Review of Abstract #401: Clinical and Prognostic Significance of 3q26 Rearrangements and Other Chromosome 3 Abnormalities in CML in Era of TKI’s. Please enter the Question! Please enter your Email Address! Review of Ab...
SOCIAL ENGAGEMENT